IL-12 and IL-27 Sequential Gene Therapy via Intramuscular Electroporation Delivery for Eliminating Distal Aggressive Tumors
- 1 March 2010
- journal article
- Published by The American Association of Immunologists
- Vol. 184 (5), 2348-2354
- https://doi.org/10.4049/jimmunol.0902371
Abstract
Eradication of residual malignancies and metastatic tumors via a systemic approach is the key for successfully treating cancer and increasing cancer patient survival. Systemic administration of IL-12 protein in an acute large dose is effective but toxic. Systemic administration of IL-12 gene by persistently expressing a low level of IL-12 protein may reduce the systemic toxicity but only eradicates IL-12-sensitive tumors. In this study, we discovered that sequential administration of IL-12– and IL-27–encoding DNA, referred to as sequential IL-12→IL-27 (IL-12 administration followed by IL-27 administration 10 d after) gene therapy, not only eradicated IL-12–sensitive CT26 tumors from 100% of mice but also eradicated the highly malignant 4T1 tumors from 33% of treated mice in multiple independent experiments. This IL-12→IL-27 sequential gene therapy is not only superior to IL-12–encoding plasmid DNA given a total of two times at a 10-d interval sequential gene therapy for eliminating tumors but also for inducing CTL activity, increasing T cell infiltration into tumors, and yielding a large number of tumor-specific IFN-γ–positive CD8 T cells. Notably, depletion of either T or NK cells during the IL-27 treatment phase reverses tumor eradication, suggesting an NK cell requirement for this sequential gene therapy-mediated tumor eradication. Both reversal of the administration sequence and coadministration of IL-12 and IL-27 impaired tumor eradication in 4T1 tumor-bearing mice. This IL-12→IL-27 sequential gene therapy, via sequential administration of IL-12– and IL-27–encoding plasmid DNA into tumor-bearing mice through i.m. electroporation, provides a simple but effective approach for eliminating inaccessible residual tumors.Keywords
This publication has 62 references indexed in Scilit:
- Intratumoral rhIL‐12 administration in head and neck squamous cell carcinoma patients induces B cell activationInternational Journal of Cancer, 2008
- Interleukin 27 negatively regulates the development of interleukin 17–producing T helper cells during chronic inflammation of the central nervous systemNature Immunology, 2006
- Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17–producing T cellsNature Immunology, 2006
- Potent Antitumor Activity of Interleukin-27Cancer Research, 2004
- Regression of tumors by IFN-α electroporation gene therapy and analysis of the responsible genes by cDNA arrayGene Therapy, 2002
- Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant siteCancer Gene Therapy, 2001
- Intramuscular electroporation delivery of IFN-α gene therapy for inhibition of tumor growth located at a distant siteGene Therapy, 2001
- Canarypox Virus-Mediated Interleukin 12 Gene Transfer into Murine Mammary Adenocarcinoma Induces Tumor Suppression and Long-Term Antitumoral ImmunityHuman Gene Therapy, 1998
- Clinical Trials: IL-12 Deaths: Explanation and a PuzzleScience, 1995
- Cytokine-Induced Tumor Immunogenicity: From Exogenous Cytokines to Gene TherapyJournal of Immunotherapy, 1993